Du är här

2014-05-15

Bionor Pharma ASA: Bionor Pharma ASA issues new share options to primary insiders

Oslo, 15. 05.2014) Bionor Pharma ASA (OSE: BIONOR) announced today that as
part of the incentive system Bionor Pharma ASA has granted a total of 1.25
million new share options to the following primary insiders.

All options are exercisable at yesterday's closing price of NOK 2.55 per
share. All options vest by 1/3 at 1. June 2015, 1/3 at 1. June 2016 and 1/3
at 1. June 2017.

Anker Lundemose, President and CEO at Bionor Pharma, has been granted 750 000
share options in Bionor Pharma. Options can be exercised from the day all
options are vested and until 14 May 2024. Following the receipt of the
options, Anker Lundemose holds 100 000 shares and 1.75 million share options
in Bionor Pharma.

The remaining granted options can be exercised from the day all options are
vested and until 48 months after the options have been vested.

Synne H. Røine, CFO at Bionor Pharma, has been granted 250 000 share options
in Bionor Pharma. Following the receipt of the options, Synne H. Røine holds
25 000 shares and 1.25 million share options in Bionor Pharma.

Gunnar Flåten, SVP Finance&Administration at Bionor Pharma, has been granted
100 000 share options in Bionor Pharma. Following the receipt of the options,
Gunnar Flåten holds 817 500 shares and 0.9 million share options in Bionor
Pharma.

Maja Sommerfelt Grønvold, CSO at Bionor Pharma, has been granted 100 000 share
options in Bionor Pharma. Following the receipt of the options, Maja
Sommerfelt Grønvold holds 319 287 shares and 0.9 million share options in
Bionor Pharma.

Arnt Ove Hovden, Director of Viral Immunology at Bionor Pharma, has been
granted 50 000 share options in Bionor Pharma. Following the receipt of the
options, Arnt Ove Hovden holds 0 shares and 250 000 share options in Bionor
Pharma.

Bionor Pharma ASA
Synne H. Røine, CFO
+47 99 22 98 92

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bionor Pharma ASA via Globenewswire

HUG#1785614

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.